• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ST. JUDE MEDICAL SWARTZ¿ INTRODUCER, UNKNOWN; TRANSSEPTAL CATHETER INTRODUCER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ST. JUDE MEDICAL SWARTZ¿ INTRODUCER, UNKNOWN; TRANSSEPTAL CATHETER INTRODUCER Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Bradycardia (1751); Hematoma (1884); Cardiac Perforation (2513)
Event Type  Injury  
Manufacturer Narrative
The results of the investigation are inconclusive since the device was not returned for analysis.The device history record was not reviewed as the batch number was not available.Based on the information received, the cause of the reported cardiac tamponade, hematomas, and bradycardia could not be conclusively determined.
 
Event Description
Related manufacturer reference: 3005334138-2019-00412, 2030404-2019-00065, 2030404-2019-00066.The following was published in jafib: journal of atrial fibrillation in an article titled "atrial fibrillation in heart failure patients with preserved or reduced ejection fraction - prognostic significance of rhythm control strategy with catheter ablation" by vecchio n, ripa l, orosco a, et al., february - march 2019.Vol 11 issue 5."atrial fibrillation (af) and heart failure (hf) often coexist with an increase in morbidity and mortality.Af catheter ablation (ca) has proved to be a safe and efficient option for hf patients, but long-term evolution and prognosis remain uncertain.The aim is to assess the efficacy and safety of ca in hf patients with af, and analyze hf long-term evolution.Consecutive patients with af and congestive hf or left ventricular ejection fraction (ef) less than 45%, who underwent ca of af between 2011 and 2016, were prospectively analyzed.It was concluded that catheter ablation of atrial fibrillation in heart failure presents an adequate success rate, improving symptoms and reducing rehospitalizations due to heart failure.However, during the study two cardiac tamponades requiring pericardiocentesis, three groin hematomas and 1 case of extreme bradycardia were observed.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SWARTZ¿ INTRODUCER, UNKNOWN
Type of Device
TRANSSEPTAL CATHETER INTRODUCER
Manufacturer (Section D)
ST. JUDE MEDICAL
5050 nathan lane north
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL
5050 nathan lane north
plymouth MN 55442
Manufacturer Contact
stephanie o' sullivan
5050 nathan lane north
plymouth, MN 55442
6517565400
MDR Report Key8841749
MDR Text Key152661795
Report Number3005334138-2019-00413
Device Sequence Number1
Product Code DYB
Combination Product (y/n)N
Reporter Country CodeAR
PMA/PMN Number
K052644
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Type of Report Initial
Report Date 07/30/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/30/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received07/12/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
INQUIRY¿ OPTIMA¿ DIAGNOSTIC CATHETER; SWARTZ¿ INTRODUCER; THERAPY¿ COOL PATH¿ DUO ABLATION CATHETER
Patient Outcome(s) Required Intervention;
-
-